Article
Endocrinology & Metabolism
Alies J. Dekkers, Friso de Vries, Amir H. Zamanipoor Najafabadi, Emmy M. van der Hoeven, Marco J. T. Verstegen, Alberto M. Pereira, Wouter R. van Furth, Nienke R. Biermasz
Summary: This study retrospectively assessed the healthcare costs and cost drivers in perioperative care for pituitary tumour patients. The results showed that length of hospital stay and complications were the main drivers of costs, and certain baseline features were also associated with higher costs.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Medicine, General & Internal
Valentina Puglisi, Elisabetta Morini, Fiammetta Biasini, Luisa Vinciguerra, Giuseppe Lanza, Placido Bramanti
Summary: This is a case report on giant pituitary tumor apoplexy, presenting a rare case of an 81-year-old female with this condition. The authors highlight the importance of prompt diagnosis and multidisciplinary management in achieving significant improvement in symptoms.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Veterinary Sciences
K. Sanders, S. Galac, B. P. Meij
Summary: Pituitary tumors are common in dogs and cats, predominantly classified as adenomas rather than carcinomas. The tumors can be hormonally active or silent, with corticotroph adenoma being the most common type in dogs and somatotroph adenoma in cats. Future studies are needed to better understand pituitary adenoma pathology and tumorigenesis mechanisms, in order to develop more effective targeted therapies.
VETERINARY JOURNAL
(2021)
Article
Clinical Neurology
Ryan Delport, James King, Mendel Castle-Kirszbaum, Tony Goldschlager, Carmela Caputo, Yi Yuen Wang
Summary: This study aimed to determine if resection of pituitary adenomas via the endoscopic endo-nasal approach (EEA) improves headaches and investigate factors that may be associated with headaches in patients with pituitary adenoma. The results showed that surgery using this method can significantly improve headaches and patients with cavernous sinus invasion are more likely to experience improvement in headaches.
WORLD NEUROSURGERY
(2023)
Article
Pharmacology & Pharmacy
Zhoubin Tan, Zhuowei Lei, Zisheng Yan, Xuetao Ji, Xiaoai Chang, Zhi Cai, Liang Lu, Yiwei Qi, Xiumei Yin, Xiao Han, Ting Lei
Summary: The study demonstrated that beta-arrestin2 signaling, rather than G protein pathways, mediates the inhibitory effects of D-2 receptor on pituitary tumor growth. The beta-arrestin2-biased agonist UNC9994 effectively suppressed pituitary tumor cell growth in vitro and in vivo by inducing intracellular reactive oxygen species. The complexity of responses of pituitary tumors to G protein signaling pathways suggests that D-2 receptor beta-arrestin2-biased ligands may offer improved therapeutic selectivity.
BRITISH JOURNAL OF PHARMACOLOGY
(2021)
Article
Clinical Neurology
Xu-jun Shu, Hui Chang, Qun Wang, Wu-gang Chen, Kai Zhao, Bo -yuan Li, Guo-chen Sun, Sheng-bo Chen, Bai-nan Xu
Summary: This study used deep learning models to predict the Ki67 labeling index (Ki67LI) status of pituitary adenoma (PA) using MRI images, achieving noninvasive preoperative prediction. The T2-weighted image model performed the best and provided clinicians with a tool for better treatment decisions.
CLINICAL NEUROLOGY AND NEUROSURGERY
(2022)
Article
Endocrinology & Metabolism
Keyi Zhang, Xuefei Shou, Hong Chen, Nidan Qiao, Wenqiang He, Zhengyuan Chen, Ming Shen, Shiqi Li, Yao Zhao, Zhaoyun Zhang, Yiming Li, Hongying Ye, Yongfei Wang
Summary: The study investigated the clinical characteristics of SCAs with positive and negative ACTH immunostaining, finding that ACTH-negative SCAs were more clinically silent and more likely to demonstrate multiple microcysts on MRI. The prevalence of SCAs, especially ACTH-negative SCAs, was substantially underestimated and should be given enough attention due to the high aggressiveness of this subtype of refractory pituitary adenoma.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Clinical Neurology
Burak Cabuk, Necdet Selim Kaya, Caner Polat, Abidin Murat Geyik, Dilek Icli, Ihsan Anik, Savas Ceylan
Summary: Surgical management of pituitary apoplexy within 21 days of symptom onset (early and delayed groups) can effectively improve headache, neuro-ophthalmic symptoms, and endocrine function, while surgery beyond 21 days (late group) may not be as effective in restoring pituitary function.
CLINICAL NEUROLOGY AND NEUROSURGERY
(2021)
Article
Clinical Neurology
Gabriel Simander, Per Olof Eriksson, Peter Lindvall, Lars-Owe D. Koskinen
Summary: This study found that intrasellar pressure (ISP) is positively correlated with tumor volume and diameter in patients with pituitary adenoma, with the coronal tumor diameter having the strongest influence on ISP elevation. Adenomas classified as parasellar invasive showed higher mean ISP than non-invasive adenomas.
Article
Clinical Neurology
Robert C. Osorio, Matheus P. Pereira, Rushikesh S. Joshi, Kevin C. Donohue, Patricia Sneed, Steve Braunstein, Philip Theodosopoulos, Ivan H. El-Sayed, Jose Gurrola, Sandeep Kunwar, Lewis S. Blevins, Manish K. Aghi
Summary: This study examined the influence of socioeconomic status (SES) on the clinical presentations and outcomes of nonfunctional pituitary adenoma (NFPA) resections. The presence of a primary care provider (PCP) was found to be the most important factor, affecting hospital lengths of stay, readmission rates, follow-up adherence, and tumor recurrence.
JOURNAL OF NEUROSURGERY
(2022)
Review
Endocrinology & Metabolism
Antonio Bianchi, Sabrina Chiloiro, Antonella Giampietro, Simona Gaudino, Rosalinda Calandrelli, Ciro Mazzarella, Carmelo Caldarella, Mario Rigante, Marco Gessi, Liverana Lauretti, Laura De Marinis, Alessandro Olivi, Alfredo Pontecorvi, Francesco Doglietto
Summary: Growth hormone-secreting adenomas exhibit a wide range of behaviors and outcomes, from mild disease to aggressive neoplasms. Treatment for patients who do not respond to surgery or first-generation somatostatin receptor ligands may involve multiple surgical, medical, and radiation treatments. Currently, there are no markers that can predict the prognosis or aggressiveness of acromegaly. A multidisciplinary approach is necessary to tailor treatment for difficult/aggressive cases, including radiation therapy, chemotherapy, and emerging treatments.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Clinical Neurology
Matthias Dottermusch, Ulrich Schueller, Christian Hagel, Wolfgang Saeger
Summary: This study investigates the epigenomic identities of hormone-negative PitNET/adenomas lacking clear transcription factor immunopositivity and challenges the legitimacy of "null cell" tumors as a distinct PitNET/adenoma subtype.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
(2023)
Article
Endocrinology & Metabolism
Zhiyu Xi, Pamela S. Jones, Masaaki Mikamoto, Xiaobin Jiang, Alexander T. Faje, Chuansheng Nie, Kathryn E. Labelle, Yunli Zhou, Karen K. Miller, Roy J. Soberman, Xun Zhang
Summary: Aggressive pituitary adenomas have increased expression of PD-L2, CD80, and CD86 compared to normal pituitary glands, and significantly higher levels of CD80 and CD86 compared to non-aggressive tumors. These findings support further research on the potential role of immune checkpoint inhibition therapy in the treatment of pituitary adenomas.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Clinical Neurology
Ben A. Strickland, Shane Shahrestani, Robert G. Briggs, Anna Jackanich, Sherwin Tavakol, Kyle Hurth, Mark S. Shiroishi, Chia-Shang J. Liu, John D. Carmichael, Martin Weiss, Gabriel Zada
Summary: SCAs are a subtype of NFAs that are more biologically aggressive, with patients presenting with more cranial neuropathy and headaches, and a shorter progression-free survival duration.
JOURNAL OF NEUROSURGERY
(2021)
Article
Oncology
Jinxian Hu, Jihu Yang, Lei Chen, Xiangbao Meng, Xiejun Zhang, Weiping Li, Zongyang Li, Guodong Huang
Summary: This study demonstrated significant differences in the gut microbiome between patients with pituitary adenoma and healthy controls, with Clostridium innocuum enriched and Fusobacterium mortiferum and Oscillibacter sp. 57_20 reduced in abundance in PA patients.
PATHOLOGY & ONCOLOGY RESEARCH
(2022)
Review
Clinical Neurology
Andreas Charidimou, Jennifer Linn, Meike W. Vernooij, Christian Opherk, Saloua Akoudad, Jean-Claude Baron, Steven M. Greenberg, Hans Rolf Jaeger, David J. Werring
Letter
Infectious Diseases
Bianca Woehrl, Jennifer Linn, Nina Lummel, Thomas Pfefferkorn, Uwe Koedel, Hans-Walter Pfister, Matthias Klein
JOURNAL OF INFECTION
(2015)
Article
Clinical Neurology
Nina Lummel, Frank Arne Wollenweber, Philippe Demaerel, Katja Bochmann, Rainer Malik, Christian Opherk, Jennifer Linn
JOURNAL OF NEUROLOGY
(2015)
Article
Clinical Neurology
Bogdana Suchorska, Nathalie L. Jansen, Jennifer Linn, Hans Kretzschmar, Hendrik Janssen, Sabina Eigenbrod, Matthias Simon, Gabriele Poepperl, Friedrich W. Kreth, Christian la Fougere, Michael Weller, Joerg C. Tonn
Article
Radiology, Nuclear Medicine & Medical Imaging
Gernot Schulte-Altedorneburg, Jennifer Linn, Mathias Kunz, Hartmut Brueckmann, Stefan Zausinger, Dominik Morhard
Article
Radiology, Nuclear Medicine & Medical Imaging
D. Daubner, S. Spieth, J. Cerhova, J. Linn, K. Kirchhof
ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN
(2016)
Review
Clinical Neurology
J. Linn
CLINICAL NEURORADIOLOGY
(2015)
Review
Clinical Neurology
Volker Puetz, Kristian Barlinn, Ulf Bodechtel, Bruce Campbell, Jennifer Linn, Johannes C. Gerber
CURRENT OPINION IN NEUROLOGY
(2016)
Article
Oncology
Amir Zolal, Tareq A. Juratli, Jennifer Linn, Dino Podlesek, Kerim Hakan Sitoci Ficici, Hagen H. Kitzler, Gabriele Schackert, Stephan B. Sobottka, Bernhard Rieger, Dietmar Krex
JOURNAL OF NEURO-ONCOLOGY
(2016)
Article
Clinical Neurology
Juergen Lutz, Niklas Thon, Robert Stahl, Nina Lummel, Joerg-Christian Tonn, Jennifer Linn, Jan-Hinnerk Mehrkens
JOURNAL OF NEUROSURGERY
(2016)
Article
Clinical Neurology
Lorenz Ertl, Dominik Morhard, Maria Deckert-Schmitz, Jennifer Linn, Gernot Schulte-Altedorneburg
Article
Clinical Neurology
N. Lummel, C. Bernau, N. Thon, K. Bochmann, J. Linn
Article
Clinical Neurology
N. Lummel, J. H. Mehrkens, J. Linn, G. Buchholz, R. Stahl, K. Bochmann, H. Brueckmann, J. Lutz
Article
Clinical Neurology
N. Lummel, M. Koch, M. Klein, H. W. Pfister, H. Brueckmann, J. Linn
CLINICAL NEURORADIOLOGY
(2016)
Article
Health Care Sciences & Services
Kevin Hadrich, Pawel Krukowski, Jessica Barlinn, Matthias Gawlitza, Johannes C. Gerber, Volker Puetz, Jennifer Linn, Daniel P. O. Kaiser
Summary: This study aimed to identify factors contributing to delays in the management of stroke patients transferred from primary hospitals to a comprehensive stroke center for endovascular therapy. The findings revealed that longer transfer time, greater transfer distance, and the use of general anesthesia were independently associated with delayed treatment. By assessing the processes and times involved in patient transfers, potentially modifiable factors for improving the workflow of stroke patients can be identified.